Core Insights - Quantum BioPharma has completed oral dosing of Lucid-21-302 (Lucid-MS) in both 180-day toxicity and toxicokinetic studies, which will support the Investigational New Drug (IND) application with the US FDA and the design of a Phase 2 trial for multiple sclerosis (MS) patients [1][2][3] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates at various development stages [1][3] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models of MS [3] Development Progress - The completion of the 180-day toxicity studies is a significant milestone, bringing the company closer to initiating the Phase 2 trial of Lucid-MS for MS patients [2][3] - The company is optimistic about the potential of Lucid-MS as a first-in-class treatment to prevent disease progression and inhibit demyelination in MS [3] Strategic Investments - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is associated with the unbuzzd™ product, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [3] - The company also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]

Core Viewpoint - Quantum BioPharma Ltd. has completed dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302, aimed at treating Multiple Sclerosis, which is a significant step towards submitting an IND application to the US FDA [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, including Multiple Sclerosis [3]. - The company is advancing its lead compound, Lucid-MS, which is a patented new chemical entity designed to prevent and reverse myelin degradation, a key mechanism in Multiple Sclerosis [3]. Development Progress - The completion of toxicity studies for Lucid-21-302 brings the company closer to initiating a Phase 2 trial for Multiple Sclerosis [2]. - The company plans to submit the IND application for Lucid-21-302 before the end of the year [2]. Strategic Investments - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition, which is involved in the OTC version of its product unbuzzd™. The agreement includes a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [3]. - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3].